Drugs / GFS101A
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05165849 | Apr → May 2022 | cancer | Zhejiang Genfleet Therapeutics Co., Ltd. | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GFS101A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05165849 ↗ |
| Route | Intravenous | “GFS101A will be administrated intravenously Q3W.” NCT05165849 ↗ |